Topic Archives: Dendreon (DNDN)

AB4 Vaccine Ignites “Fierce Bidding War” for “Small Texas Lab?”

Remember Ernie Tremblay’s pitch about a “tiny South Texas lab” that was about to cure every disease using its revolutionary CD19 Cancer Vaccine technology, and ignite a bidding war following its fantastical release of exciting information on June 23? Well, it’s back. Not the stock, that’s still languishing around where it was before Tremblay got […]

Gumshoe BioDimSum II: Corralling the “A” Biotechs Plus a New Long Selection

[Ed. Note: Dr. KSS writes for our Irregulars about medicine and biotech stocks. As always, he has agreed our trading restrictions, and his words and opinions are his own. You can find all of his previous articles here. And now, for some dim sum….] Greetings Irregulars, and welcome to Stock Gumshoe’s festive second BioDimSum shindig, a periodic round-up […]

Comments

  • Avatar

    Never pay that much money for any advise service,I didn't subscribe to his microcap advisory and I new that he was teasi...

  • SoGiAm

    $ONCS ow 8-K filed > https://ir.oncosec.com/all-sec-filings/content/0001493152-18-000522/form8-k.htm If you have any q...

  • Dr. KSS MD PhD

    Roger: Here's how I view Immune Design. As of 2013-2014, the world was going like mad after tumor vaccine approaches to ...

  • Dr. KSS MD PhD

    Hard to believe any publication would be lauded for having pounded the table on Dendreon and Arena, Dendreon is the most...

  • Avatar

    I believe the author might read DR KSS and get some ideas from here and, when the timing is right, makes a recommendatio...

  • Avatar

    Before BIOC, ARTH and SCYX he nailed a couple other biotech winners, Dendreon for cancer and Arena Pharm for lorcaserin ...

  • Avatar

    Good biotech picks are virtually immune from economic conditions (but can be affected by political conditions). One exa...

  • Dr. KSS MD PhD

    One other thing that looks dubious to me about the JUNO situation is that, in addition to be helmed by formers of Dendre...

  • Avatar

    Changed Sleuth column to Watchlist, added date for $IBIO. Updated comment for $INO, added. Galena/NW Bio added with same...

  • sogiam

    INO from ZKSS 2/15/15 Spreadsheet: They have had some mildly good data, but it is still junk science: nonspecific effec...

  • Dr. KSS, MD PhD

    Up at WSJ Biotech’s Rally Fuels Bubble Fears As Valuations Skyrocket and Nasdaq Nears Record, Anxiety Builds A Gi...

  • Dr. KSS, MD PhD

    We covered $INO in great depth last spring....the cattle prod DNA vaccine company. They are giving constructs via intram...

  • arch1

    DR KSS Thank you for informing my ignorance,I would like to hear more of $BLCM. I wrongly assumed they were following ...

  • Dr. KSS, MD PhD

    Elliot: our relative present Sedleckopenia has been noticed at least by me, and you are valued for your trenchant and th...

  • Avatar

    And former Dendreon CEO's new venture http://www.xconomy.com/wisconsin/2014/10/13/former-dendreon-ceo-gold-working-on-n...

  • JohnM

    DR KSS - I posted a reply/question on comment #136 re Dendreon. Just thought it might get buried....

  • Dr. KSS, MD PhD

    Om: about Opexa. In earlier threads we talked about dendritic cell vaccines, such as those by Dendreon, Galena, NW Bio. ...

  • Dr. KSS, MD PhD

    Dendreon CEO stepping down for "personal reasons," Is realizing you have scammed a nation of men with prostate cancer a ...

  • Dr. KSS, MD PhD

    Terje: And I am sure everyone in this forum is quite glad you are among the living. If you are really interested in t...

  • Avatar

    Here's a tentative shorting list if anyone is interested. Be careful - I did it kinda fast. Maybe someone can clean it...

  • Dr. KSS, MD PhD

    Ah, JZ. So the idea of taking patients in whom therapy for melanoma has failed....that excites you? Despite the best eff...

  • Avatar

    Hmm - your comments regarding Provenge caught my attention. I got into Dendreon many years ago at $5.48 and sold about ...

  • Dr. KSS, MD PhD

    Kenny, haven't seen the Feuerstein piece, but DC in DCVax is dendritic cell, and I think we can make dendritic cell vacc...

  • DBMD

    To Scott Postma The suggestion to read the irregulars info at SG would possibly save you lots of money. Dr KSS gives hi...

  • Dr. KSS, MD PhD

    You are here, John Davis, to market the newsletter for which you have authored articles supporting ScanCell. My understa...

  • karmaswimswami

    Biocqr: Do you ever get the sense that the FDA is this indolent addled mood-ring of a dysfunctional agency? That it is s...

  • karmaswimswami

    To the insuperable Subra: You probably know this but in case: http://www.nasdaq.com/quotes/institutional-portfolio/sab...

  • Avatar

    Karmaswimswami, thank you for your kind words and your Prostate cancer / Dendreon discussion earlier. I don't want to...

  • karmaswimswami

    I think there are some longs here in Galena (GALE). Because it is on subject, let me say this: what they are doing may b...

  • karmaswimswami

    Alan: it is sobering if you think about it really. It is wrong to predicate an investment on the idea that people are du...

  • karmaswimswami

    One other thing about the Dendreon debate is that it does have object lessons for all of us about the differences betwee...

  • karmaswimswami

    Jack, they have been on a watch list of mine for a while. Please don't take it personally, but I cannot see putting anyt...

  • Avatar

    PS. I have now idea what Dendreon is, but I intend to find out. If i don't like the product i may still buy the stock ...

  • Avatar

    I'm not sure if T cell therapy is the same as dendritic cell therapy, but a couple of companies have caught my eye relat...

  • Avatar

    Here's a"teaser" from Agora's "5-Minute Forecast" Anyone have a clue??? [Paste-in follows]...

  • Avatar

    Here's a"teaser" from Agora's "5-Minute Forecast" Anyone have a clue??? [Paste-in follows...

  • Avatar

    I own shares of an Australian company called Prima Biomed (PRR):ASX? They have a product called C-Vac which, from what I...

  • Avatar

    I seem to remember someone touting that Dendreon was going to come out with horrible results and they urged shorting the...

  • Avatar

    Shoe, If you'd like to turn that turkey into a turducken (http://en.wikipedia.org/wiki/Turducken)you can use the Den...

  • Avatar

    I'm an Alliance Member over at Stansberry & Associates, so I've seen all their products and used most of them. So f...

  • Avatar

    First of all, with regard to Leeb. If I remember correctly, and I am pretty sure I do, his "personal Finance" Newslette...

  • Avatar

    First trade paid for my subscription! Then there was Dendreon, that paid for like 1,000 subscriptions... 300% gain in l...

  • Avatar

    Well, big news from Dendreon this morning -- and if anyone decided to buy puts on Dendreon or sell the shares short, I i...

  • Avatar

    There will be no review committee. Provenge already went to a Biologics division advisory committee on March 29, 2007 t...

  • Avatar

    No, MITI is the better solution for the first one, the "active immunity" one for which I proposed Dendreon....

  • Avatar

    Geez, there goes my teaser for the one I hadn't had a chance to write up yet. Ah, well, I'll write about it later this ...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch